Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Recipients

Scholarships Awarded to Nine Students Affected by Dermatologic Conditions

Bausch Health Companies Inc. (NYSETSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the recipients of their 2021 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 to pursue their undergraduate or graduate degrees.

"For nine years, Ortho Dermatologics has supported students in achieving their higher education goals through our Aspire Higher scholarship program. Beyond the demands of their schooling and extracurricular activities, these students have also had to manage the burden of living with a skin condition," said Scott Hirsch , senior vice president and chief strategy officer, Bausch Health, and president, Ortho Dermatologics. "The stories our 2021 scholarship recipients shared with us are inspiring, and we are honored to provide them with this award to recognize their achievements and help them pursue their academic aspirations."

The 2021 honorees were chosen from nearly 150 applications and were selected in part due to their essays overviewing their educational journeys while living with dermatologic conditions and the role a health care professional played in treating the condition. The applications were judged by an independent panel of dermatologists from across the country.

The Aspire Higher scholarship program recognizes students across a wide range of educational pursuits, with scholarships in three categories, including the Undergraduate Scholar Awards, the Graduate Scholar Awards, and the Today's Woman Scholar Awards for mothers pursuing undergraduate or graduate degrees.

The 2021 Aspire Higher scholarship program recipients are:

  • Undergraduate Scholar Awards
    • Sonia Goyal , Clarksville, Md. – The George Washington University
    • Anhthy Nguyen , Hayward, Calif. University of California, Los Angeles
    • Olivia Kenyon , West Chester, Pa. University of Florida
  • Graduate Scholar Awards
    • McKenzie White , Bakersfield, Calif. – Rocky Vista University College of Osteopathic Medicine
    • Maria Rose Belding , Washington, D.C. Georgetown University School of Medicine
    • Brooke Abzug , Delray Beach, Fla. University of Florida : Department of Occupational Therapy
  • Today's Woman Scholar Awards
    • Megan Gambino , Doylestown, Pa. – Delaware Valley University
    • Hillary Hardin , North Bergen , N.J. – Felician University
    • Sarah Ramirez , Humble, Texas Lake Erie College of Osteopathic Medicine (LECOM), Bradenton Campus

"Living with a skin condition can often be very difficult, especially when managing school – much of which was particularly challenging this year due to remote learning – and other activities. Thanks to the generosity of Ortho Dermatologics, I will be one step further toward achieving my goal of receiving a degree in Physical Therapy and Exercise Science," said Hillary Hardin , Felician University, North Bergen, N.J.

To learn more about the Aspire Higher scholarship program and to see stories from previous scholarship recipients, please visit www.AspireHigherScholarships.com . The 2022 Aspire Higher scholarship program will be accepting applications in early 2022.

About the Aspire Higher Scholarship Program
Since 2013, the Aspire Higher scholarship program has awarded 60 scholarships, providing students a total of $648,000 toward their higher education on campuses nationwide. The Aspire Higher scholarship program is now funded through the Bausch Foundation.

About the Bausch Foundation
In 2017, the Bausch Foundation was established to improve the lives of patients globally by providing access to safe, effective medicines and by financially supporting health care education and causes. Since its inception, the Bausch Foundation has contributed millions of dollars worth of financial and product donations to global charitable health organizations.

About Ortho Dermatologics
Ortho Dermatologics is one of the largest dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. In addition, the Ortho Dermatologics portfolio also includes several leading medical device systems for aesthetic applications, such as skin tightening and resurfacing, laser hair removal and other preventative therapeutic skin care treatments. More information can be found at www.ortho-dermatologics.com .

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Ortho Dermatologics is a trademark of Ortho Dermatologics' affiliated entities.
© 2021 Ortho Dermatologics' affiliated entities.
ORD.0126.USA.21

Bausch Health Investor Contact:
Arthur Shannon
arthur.shannon@bauschhealth.com
(514) 865-3855
(877) 281-6642 (toll free)

Bausch Health Media Contact:
Lainie Keller
lainie.keller@bauschhealth.com
(908) 927-1198

Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

(PRNewsfoto/Valeant Pharmaceuticals Interna)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/ortho-dermatologics-announces-2021-aspire-higher-scholarship-recipients-301343645.html

SOURCE Bausch Health Companies Inc.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

SMART trial one-year data demonstrates Medtronic Evolut TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), were presented as a late breaking clinical trial at the American College of Cardiology Annual Scientific Session and simultaneously published in The New England Journal of Medicine . The one-year results of the SM all A nnuli R andomized T o Evolut or SAPIEN (SMART) Trial in individuals with aortic stenosis (AS) with small aortic annuli (SAA) demonstrated noninferior clinical outcomes and superior valve performance as measured by bioprosthetic valve dysfunction performance for the Evolut™ TAVR platform compared to the SAPIEN™ platform.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

New survey uncovers lack of awareness around heart valve disease and risk factors among women

Despite prevalence of chronic conditions associated with aortic stenosis in women over 65, the majority have never been referred to a cardiologist; Racial disparities may present further opportunities for awareness amongst women at risk for cardiovascular disease

Medtronic plc, a global leader in healthcare technology, today unveiled topline findings of its comprehensive survey on women's perceptions and knowledge of risk factors, treatment patterns, and preventive care practices related to heart valve disease. The survey is endorsed by Women as One and was conducted by Wakefield Research sampling 1,000 women in the United States (U.S.) aged 50 and older.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for UCERIS Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the first public drug plan listings for PrUCERIS® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults.1

UCERIS is now available for patients through the public drug plans of five Canadian provinces: Ontario, Quebec, Saskatchewan, New Brunswick and Nova Scotia.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations

Salix Pharmaceuticals Releases Fourth Annual Patient Perspectives IBS Impact Report

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today for IBS Awareness Month announced the results from the fourth edition of its annual survey of U.S adults living with irritable bowel syndrome (IBS) or chronic idiopathic constipation (CIC). ​Developed as a nationwide survey conducted in partnership with Fairleigh Dickinson University Poll (FDU Poll), more than 850 IBSCIC patients were surveyed to better understand their experiences. The findings illustrate the current behaviors and experiences of the IBS and CIC patient population

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 24, 2024

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2024 before the market opens on Wednesday, April 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT.

During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 105588. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com . The earnings press release and related information can also be found in that section of our website under the heading "Financials." A replay of the call will be available under "News, Events & Presentations" through Wednesday, May 8, 2024.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
CardieX Limited

Cardiex Completes HEARTsense Wearable Study and Secures US Wearable Patent

CARDIEX Limited (ASX:CDX) (CARDIEX, the Company) is pleased to announce the successful completion of two significant milestones in the commercialization of its wearable biomarker technology.

Keep reading...Show less

Latest Press Releases

Related News

×